Ocuphire Pharma Investor Update
RM
31
Reversal of Mydriasis Unmet Need & Landscape
With No Commercially Available Treatment, Nyxol is Uniquely Positioned as a New Reversal Drop
The Problem
At many annual eye exams and specialty
visits, pupils are pharmacologically
dilated, impairing vision for 6-24 hours
Dilated eyes experience:
Heightened sensitivity to light
Inability to focus, headaches
Difficulty reading, working & driving
Halos and glare
Cycloplegia (loss of accommodation)
Source
1. Optician (2012)-Mydriatic Drugs: Practical Considerations
2. Pilocarpine FDA Label (2017)
3. Optos plc Pricing
No Currently Available Treatments
100M
Annual Eye Dilations
●
Current Landscape:
Rare off-label use of cholinergic
agonists (e.g., pilocarpine) given
ciliary muscle safety issues1,2
Optomap® is offered by
optometrists to avoid dilations for
-$50 cash-pay, however images
may provide limited view of
retina and disease pathology³
Nyxol's MOA Uniquely Suited As A Reversal Drop For Dilations
Ocuphire
PHARMAView entire presentation